Citation only
via OpenAlex
NAD-elevating Interventions for Cardiometabolic Disease
The Journal of Clinical Endocrinology & Metabolism · 2023 · ▲ 2 citations
Genomic instability
Epigenetic alterations
Loss of proteostasis
Dysbiosis
Deregulated nutrient-sensing
Mitochondrial dysfunction
Cellular senescence
Stem-cell exhaustion
Chronic inflammation
Human
Review
Abstract
Cardiometabolic diseases, such as atherosclerosis, diabetes, obesity, dyslipidemia, and hypertension, are major causes of mortality, morbidity, and disability in older adults, and aging is one of the most important risk factors for their development. Major advances have been made in the last approximately 30 years about our understanding of the biology of aging at the molecular and cellular levels. Notably, several lines of research conducted in model organisms have demonstrated that aging is a highly regulated process that is under the control of intrinsic (genetic) and extrinsic (diet, environment) factors. These findings have led to the geroscience hypothesis, which posits that interventions that target basic mechanisms of aging may be helpful for the prevention and treatment of multiple age-related pathologies (1). The cellular processes underlying the biology of aging have been referred to as the “hallmarks” or “pillars” of aging, and include mitochondrial function, cellular metabolism, epigenetics, proteostasis(definition), macromolecular damage, stem cell dysfunction, dysbiosis, cellular senescence(definition), and inflammation (2). Several nutraceutical and pharmacological interventions are being developed to modulate these processes and target age-related disease. One of these interventions involves raising levels of nicotinamide adenine dinucleotide (NAD). NAD and its phosphorylated form (NADP) play essential roles in redox and biosynthetic reactions, including synthesis of adenosine triphosphate (ATP), nucleic acids, steroids, and fatty acids. NAD also protects against oxidative stress and serves as a cosubstrate for many enzymes (eg, sirtuins) that control key cellular processes, including gene expression, DNA repair, proteostasis, calcium handling, and cell death (reviewed in (3)). Interest in interventions to increase NAD levels stem from observations, mostly from animal models, that NAD levels decline during aging and under pathologic conditions such as diabetes, obesity, neurodegeneration, and acute infections. Furthermore, several studies to test interventions that raise NAD levels in rodents have reported improvements in many of these pathologies and overall health (reviewed in (4)). Despite the largely positive data from animal studies, there are limited data from prospective human trials demonstrating the safety and efficacy of NAD-elevating interventions. Strategies to raise NAD include (among others) administration of NAD precursors/intermediaries, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), or blocking NAD-consuming enzymes like cluster of differentiation (CD)38; this enzyme increases with aging and some pathological conditions. Pencina et al (5) recently reported findings from a 28-day placebo-controlled trial (n = 30) aimed at evaluating the bioavailability, tolerability, and physiological effects of a microcrystalline NMN formulation in middle-aged overweight/obese adults. The authors reported acceptable tolerability and no significant toxicities from NMN administration. NMN administration resulted in significant increases in circulating levels of NAD and several of its metabolites. NMN administration afforded benefits in some cardiometabolic outcomes, including reduced total body weight, blood pressure, and low-density lipoprotein cholesterol concentrations. Insulin sensitivity, measured with the homeostatic model assessment for insulin resistance index (HOMA-IR), did not change with NMN. Prior studies that used the insulin clamp technique reported neutral (6) or beneficial (7) effects from NAD precursors/intermediaries on insulin sensitivity. Pencina et al (5) reported mostly neutral effects of NMN on muscle function. They used magnetic resonance spectroscopy to measure levels of NAD and high-energy phosphates (ATP, phosphocreatine) in skeletal muscle at resting and postcontraction conditions, and found no differences between the NMN and placebo groups with regard to muscle levels of these metabolites or postcontraction phosphocreatine recovery (an indicator of ATP synthesis capacity). A prior study using NR showed elevations in NAD concentrations in brains from patients with Parkinson disease, as measured in vivo by magnetic resonance spectroscopy (8). The recent study from Pencina and colleagues (5) adds to a growing number of studies in human populations demonstrating the feasibility of interventions to increase NAD. Despite their limitations, namely small sample sizes and short duration, these proof-of-concept studies provide a solid foundation for the design of future, well-powered trials that are necessary to further evaluate optimal dosing, safety, cellular effects, mechanism of action, and, most important, clinically relevant outcomes on healthy individuals and patients suffering from age-related pathologies. N.M. participated in an investigator-initiated study testing the effects of NR. The formulation was provided at no cost by Chromadex, which had no role in the study design, study conduct, or data analysis. adenosine triphosphate nicotinamide adenine dinucleotide nicotinamide mononucleotide nicotinamide riboside
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1210/clinem/dgad120
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Musi, N. (2023). NAD-elevating Interventions for Cardiometabolic Disease. <em>The Journal of Clinical Endocrinology & Metabolism</em>. https://doi.org/10.1210/clinem/dgad120
Vancouver
Musi N. NAD-elevating Interventions for Cardiometabolic Disease. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad120.
BibTeX
@article{nicolas2023NADele,
title = {NAD-elevating Interventions for Cardiometabolic Disease},
author = {Nicolas Musi},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad120},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Lausanne 2010
Open access · US-GOV
In French AGIR Means to Get Into Action. This is the Generic Title of Our Study.
Frontiers in Aging Neuroscience 2010
Open access · CC-BY
Selective neuronal vulnerability to oxidative stress in the brain
Journal of Biomedical Science 2019
Open access · CC-BY
Implications of altered NAD metabolism in metabolic disorders
Frontiers in Aging Neuroscience 2023
Open access · CC-BY
Systematic review of 31P-magnetic resonance spectroscopy studies of brain high energy phosphates and membrane phospholipids in aging and Alzheimer's disease
Nature Communications 2021
Open access · CC-BY
Impact of aging and exercise on skeletal muscle mitochondrial capacity, energy metabolism, and physical function
International Journal of Research and Review 2023
Open access · OA